Drugs Made In America Acquisition II reported a net income of $4,187,050 for the period driven primarily by $4,933,800 of interest income on its trust account, while recording a net loss of $151,719 for the interim period Aug 23, 2024–Dec 31, 2024 reflecting general and administrative expenses. The company has no operating revenues as it remains in a pre-combination stage and continues to incur public-company costs. Activities during the period focused on completing the IPO, maintaining the trust, and preparing for an initial business combination in the pharmaceutical sector.
Financial Highlights
- Net Income: $4,187,050, primarily from $4,933,800 interest income on the trust account.
- Net Loss (Aug 23, 2024–Dec 31, 2024): $151,719, comprised of general and administrative costs.
- Revenue / Sales: Omitted from Part II Item 7/Item 8; not presented.
- Gross Profit: Omitted from Part II Item 7/Item 8; not presented.
- Net Income Per Share: Omitted from Part II Item 7/Item 8; not presented.
Business Highlights
- IPO & Trust Funding: Completed a $500 million initial public offering and placed the proceeds in a trust to fund an initial business combination focused on pharmaceuticals.
- Stage of Operations: Early-stage blank-check company with no operating revenue; primary activities are searching for and performing due diligence on potential targets.
- Financing & Runway: Incurs ongoing public-company administrative and listing costs; secured bridge convertible notes and an LOI for up to $1.4 million to cover transaction and audit expenses.
- Sponsor & Governance: Sponsor acknowledged a limited role and agreed to cooperate on sponsor share transfers; an administrative services arrangement was cancelled.
- Outlook: Continued focus on identifying and completing an initial business combination in the pharmaceutical space, with financing arrangements in place to support transaction-related costs.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.